San Francisco, Aug. 28th, 2017 – RECARDIO, announced that the European Patent Office (EPA) has issued the notice of allowance for its innovative use patent for the treatment of ischemic diseases.
This patent is the result of research conducted since 2006, part of RECARDIO’s broad patent claims and covers the combination therapy of G-CSF and any DPP-IV compound in cardiovascular diseases. The company’s intellectual property estate enables now efficient and protected development of its innovative cardiac therapies in all major markets. In addition RECARDIO has exklusive protection for its lead drug Dutogliptin in all these markets.
Dr. Roman Schenk, RECARDIO’s Executive Chairman and founder said: “ The issuance of this umbrella patent is an additional major step towards our strategy to protect and establish our regenerative therapies and to safeguard its marketing in key global markets”.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, Dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is initiating a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/